No controlled human replication of the ibogaine ketamine-abstinence finding is published within 12 weeks; follow-up stays at case-series/preclinical level.

Scientists found a surprising result suggesting ibogaine (a powerful psychedelic from an African plant) might help people stay off ketamine (a dissociative drug). But turning one interesting case report into a properly controlled study — where you have comparison groups, safety screening, and ethics board approval — takes months to years, not weeks. So for now, this remains a 'promising but unproven' signal.

Controlled ibogaine trials take quarters to years given IRB, cardiac screening, and funding hurdles. A single case cannot spawn RCT data this fast.